Publication | Closed Access

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

MedicineMelanomaPathologyVal600lys Braf-mutant MelanomaNeurologyCancer TreatmentOncologyRadiation OncologyMolecular Oncology